Gish Paula, Mosholder Andrew D, Truffa Melissa, Johann-Liang Rosemary
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, The United States Food and Drug Administration, Silver Spring, MD 20993, USA.
J Pediatr. 2009 Sep;155(3):432-4. doi: 10.1016/j.jpeds.2009.01.074.
We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.
我们回顾了美国食品药品监督管理局发布的与奥昔布宁相关的中枢神经系统（CNS）抗胆碱能效应的上市后报告。考虑到按年龄组划分的国内用药情况，与成年患者相比，儿科患者报告的中枢神经系统不良事件病例数量不成比例地更高。中枢神经系统刺激在儿科病例中较为突出。
